Univariate and multivariate Cox regression model for RFS and OS by individual cytogenetic lesion
| . | RFS . | OS . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | Unadjusted HR . | Unadjusted 95% CI . | Unadjusted P . | Adjusted HR . | Adjusted 95% CI . | Adjusted P . | Unadjusted HR . | Unadjusted 95% CI . | Unadjusted P . | Adjusted HR . | Adjusted 95% CI . | Adjusted P . |
| KMT2A rearrangement, all | ||||||||||||
| All others KMT2Ar, all | REF 1.597 | REF 0.862-2.958 | REF .1365 | REF 1.943 | REF 0.903-4.179 | REF .0892 | REF 1.899 | REF 0.996-3.619 | REF .0514 | REF 2.589 | REF 1.153-5.811 | REF .0212 |
| KMT2A rearrangement, infant | ||||||||||||
| All others KMT2Ar, infant leukemia* | REF 0.966 | REF 0.353-2.649 | REF .9471 | REF 0.774 | REF 0.207-2.897 | REF .7040 | REF 1.804 | REF 0.724-4.498 | REF .2052 | REF 3.639 | REF 1.039-12.746 | REF .0434 |
| Ph+ | ||||||||||||
| All others Ph+ | REF 0.222 | REF 0.054-0.904 | REF .0356 | REF 0.304 | REF 0.073-1.267 | REF .1021 | REF 0.305 | REF 0.075-1.245 | REF .0981 | REF 0.409 | REF 0.098-1.713 | REF .2211 |
| Ph-like | ||||||||||||
| All others Ph-like | REF 0.614 | REF 0.193-1.952 | REF .4087 | REF 0.686 | REF 0.208-2.267 | REF .5366 | REF 0.701 | REF 0.255-1.924 | REF .4903 | REF 0.777 | REF 0.274-2.203 | REF .6351 |
| Hyperdiploid | ||||||||||||
| All others Hyperdiploid | REF 0.451 | REF 0.182-1.117 | REF .0851 | REF 0.445 | REF 0.177-1.120 | REF .0855 | REF 0.577 | REF 0.250-1.333 | REF .1984 | REF 0.572 | REF 0.243-1.345 | REF .2003 |
| ETV6/RUNX1 | ||||||||||||
| All others ETV6/RUNX1 | REF 1.626 | REF 0.780-3.388 | REF .1946 | REF 1.527 | REF 0.709-3.290 | REF .2797 | REF 1.201 | REF 0.483-2.984 | REF .6936 | REF 1.209 | REF 0.475-3.077 | REF .6903 |
| . | RFS . | OS . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | Unadjusted HR . | Unadjusted 95% CI . | Unadjusted P . | Adjusted HR . | Adjusted 95% CI . | Adjusted P . | Unadjusted HR . | Unadjusted 95% CI . | Unadjusted P . | Adjusted HR . | Adjusted 95% CI . | Adjusted P . |
| KMT2A rearrangement, all | ||||||||||||
| All others KMT2Ar, all | REF 1.597 | REF 0.862-2.958 | REF .1365 | REF 1.943 | REF 0.903-4.179 | REF .0892 | REF 1.899 | REF 0.996-3.619 | REF .0514 | REF 2.589 | REF 1.153-5.811 | REF .0212 |
| KMT2A rearrangement, infant | ||||||||||||
| All others KMT2Ar, infant leukemia* | REF 0.966 | REF 0.353-2.649 | REF .9471 | REF 0.774 | REF 0.207-2.897 | REF .7040 | REF 1.804 | REF 0.724-4.498 | REF .2052 | REF 3.639 | REF 1.039-12.746 | REF .0434 |
| Ph+ | ||||||||||||
| All others Ph+ | REF 0.222 | REF 0.054-0.904 | REF .0356 | REF 0.304 | REF 0.073-1.267 | REF .1021 | REF 0.305 | REF 0.075-1.245 | REF .0981 | REF 0.409 | REF 0.098-1.713 | REF .2211 |
| Ph-like | ||||||||||||
| All others Ph-like | REF 0.614 | REF 0.193-1.952 | REF .4087 | REF 0.686 | REF 0.208-2.267 | REF .5366 | REF 0.701 | REF 0.255-1.924 | REF .4903 | REF 0.777 | REF 0.274-2.203 | REF .6351 |
| Hyperdiploid | ||||||||||||
| All others Hyperdiploid | REF 0.451 | REF 0.182-1.117 | REF .0851 | REF 0.445 | REF 0.177-1.120 | REF .0855 | REF 0.577 | REF 0.250-1.333 | REF .1984 | REF 0.572 | REF 0.243-1.345 | REF .2003 |
| ETV6/RUNX1 | ||||||||||||
| All others ETV6/RUNX1 | REF 1.626 | REF 0.780-3.388 | REF .1946 | REF 1.527 | REF 0.709-3.290 | REF .2797 | REF 1.201 | REF 0.483-2.984 | REF .6936 | REF 1.209 | REF 0.475-3.077 | REF .6903 |
Multivariate model adjusted for age, sex, blinatumomab exposure, and bone marrow disease at infusion.
Censored at 24 months because of small sample size beyond 24 months.